Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAetna golimumab Coverage & Prior Auth Policy | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0790

    Golimumab (Simponi and Simponi Aria)

    Customize your policy alerts

    Sign up for Aetna Policy 0790 alerts

    Get alerted when Policy 0790 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage, dosing, coding, and utilization policy for golimumab (Simponi subcutaneous and Simponi Aria intravenous) including indications, continuation of therapy, experimental uses, and dosage guidance for providers and payers.

    Policy Summary
    PayerAetna
    PolicyGolimumab (Simponi and Simponi Aria)
    Policy CodePolicy 0790
    Change TypeNo material changes
    Effective DateJul 10, 2009
    Last ReviewJul 31, 2026
    Next Review DateAug 27, 2026
    Key ActionObtain prior authorization and document indication, prior therapies, dosing regimen, and latent TB testing before initiating golimumab.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2formulations
    multiplelabeled indications
    07/10/2009policy effective
    07/31/2026last review
    08/27/2026next review

    Coverage Criteria for Golimumab (Simponi / Simponi Aria)

    Initial coverage criteria

    Covered when the use matches FDA-approved indications and regimens

    FDA-approved indication and dosing: Patient has diagnosis consistent with FDA-approved indications for Simponi or Simponi Aria (e.g., adult RA, adult PsA, adult AS, adult UC; pediatric pJIA and pediatric PsA for Simponi Aria; pediatric UC for Simponi subcutaneous when meeting weight/age criteria)

    References: FDA approvals and label expansions cited

    Prior therapy or disease severity consistent with trials/guidance: For indications where trials enrolled patients with inadequate response to conventional therapy (e.g., MTX for RA, conventional UC therapy for UC), documentation should show inadequate response, intolerance, or contraindication to those therapies as applicable

    Aligned with trial inclusion criteria and guideline recommendations (ACR, EULAR)

    Dosing matches studied/approved regimen: Prescribed dosing and schedule match the FDA-approved regimen or documented weight-/BSA-based pediatric dosing used in studies (e.g., IV Simponi Aria 2 mg/kg at weeks 0 and 4 then every 8 weeks; SC Simponi UC induction 200 mg Week 0, 100 mg Week 2 then 100 mg every 4 weeks)
    Policy Summary
    PayerAetna
    PolicyGolimumab (Simponi and Simponi Aria)
    Policy CodePolicy 0790
    Change TypeNo material changes
    Effective DateJul 10, 2009
    Last ReviewJul 31, 2026
    Next Review DateAug 27, 2026
    Key ActionObtain prior authorization and document indication, prior therapies, dosing regimen, and latent TB testing before initiating golimumab.
    SourceLink
    On This Page
    Coverage Criteria for Golimumab (Simponi / Simponi Aria)Coding and Product InformationProvider Requirements, Prior Authorization, and DocumentationBackground and Therapy OverviewDefinitions and References

    Pediatric SC dosing studied by BSA in PURSUIT 2; label provides weight-tiered recommendations

    Continuation therapy

    Continuation/maintenance coverage considerations

    Response to therapy: Continuation can be supported when documentation shows clinical response or maintenance of remission consistent with trial endpoints (e.g., maintained clinical response through week 54 in PURSUIT maintenance study)

    Examples: maintenance of clinical response or remission per study definitions

    Indications with explicit continuation headings: Continuation of therapy headings are present for Psoriatic arthritis (PsA), Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), Ulcerative colitis (UC), and Immune checkpoint inhibitor-related toxicity.

    Detailed continuation criteria not present in this extracted segment.

    Pediatric indications

    Pediatric-specific coverage considerations

    Pediatric UC and pJIA criteria: For pediatric ulcerative colitis, patient weight >= 15 kg and meeting disease severity and prior therapy criteria similar to the PURSUIT 2 trial; for polyarticular juvenile idiopathic arthritis (pJIA) and pediatric psoriatic arthritis, dosing and age criteria should match FDA approvals (Simponi Aria approved in patients 2 years of age and older)weight >= 15 kg

    PURSUIT 2 and Simponi Aria pediatric approvals cited

    Coverage criteria for rheumatoid arthritis

    Covered when aligned with guideline-based escalation and clinical evidence:

    RA initial coverage: Patient has rheumatoid arthritis and has not achieved treatment targets with conventional DMARD therapy (e.g., methotrexate) or has documented contraindication/intolerance to those agents

    EULAR guidance recommends methotrexate first-line; Appendix A lists acceptable reasons to avoid methotrexate (e.g., pregnancy, liver disease)

    Evidence of benefit with IV golimumab: For IV golimumab (Simponi Aria), randomized trial evidence shows superior ACR20/50 responses and inhibition of radiographic progression when used with methotrexate (e.g., 59% ACR20 at week 14 versus 25% for placebo plus MTX)

    Trial data demonstrate clinical and radiographic benefit when added to MTX

    Safety assessment: Document pre-treatment screening and ongoing monitoring for infections (including TB) and other safety risks per prescribing information and referenced guidelines

    Serious infections and deaths were reported in trials; documentation expected

    Continuation of Therapy (by indication)

    Continuation of therapy sections (headings present for multiple indications)

    Continuation indications listed: Continuation of therapy headings are present for Psoriatic arthritis (PsA), Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), Ulcerative colitis (UC), and Immune checkpoint inhibitor-related toxicity.

    Detailed continuation criteria not present in this extracted segment.

    Coverage-relevant criteria summarized from background and guideline references

    Coverage aligned to FDA-approved and compendial uses; prior trials of conventional therapies are referenced where applicable.

    FDA-approved indications: Golimumab (Simponi) is indicated for: moderately to severely active rheumatoid arthritis in adults in combination with methotrexate; active psoriatic arthritis in adults alone or with methotrexate; active ankylosing spondylitis in adults; and moderately to severely active ulcerative colitis in adults and pediatric patients weighing at least 15 kg.

    Derived from prescribing information.

    Compendial/off-label indications: Compendial uses include non-radiographic axial spondyloarthritis and immune checkpoint inhibitor-related inflammatory arthritis; UpToDate recommends consideration of nr-axSpA patients who failed two different NSAIDs consecutively.

    Off-label/compendial support cited in document.

    Prior therapy expectations: Guidance (NICE and UpToDate cited) recommends trials of conventional DMARDs including methotrexate for RA and trials of two NSAIDs for nr-axSpA prior to TNF inhibitor use unless contraindicated.2 DMARDs for RA; 2 NSAIDs for nr-axSpA

    Policy text references these expectations.

    Experimental, Investigational, or Unproven

    Uses considered experimental, investigational, or unproven

    Prohibited/Unproven uses: Concomitant use of golimumab with any other biologic or targeted synthetic drug for the same indication is considered experimental/investigational. Intravenous golimumab is considered experimental/investigational for indications including Behcet's disease, Crohn's disease, non-infectious uveitis, panuveitis, posterior uveitis, and scleritis. Subcutaneous golimumab is considered experimental/investigational for indications including asthma, Behcet's, Crohn's disease, non-infectious uveitis, panuveitis, posterior uveitis, sarcoidosis, and scleritis.

    This list is not all-inclusive per policy text.

    Other indications — evidence summary

    Other indications discussed (generally investigational or limited evidence):

    Asthma: Randomized trial in severe uncontrolled asthma failed to show benefit and demonstrated unfavorable risk-benefit, leading to early discontinuation

    Not supported for asthma

    Crohn's disease: UpToDate and review evidence do not recommend golimumab for moderate to severe Crohn's disease in adults; limited observational data exist regarding dual biologic therapy in refractory cases

    Considered unsupported or investigational

    Sarcoidosis: Randomized trials are lacking and controlled trials did not show benefit for pulmonary sarcoidosis; evidence insufficient to support routine use

    Evidence insufficient

    Non-infectious uveitis: Case series and small non-randomized studies suggest possible benefit in refractory non-infectious uveitis but evidence is limited and not definitive

    Considered limited evidence; may be reserved for refractory cases with specialist documentation

    Aetna considers use of golimumab (intravenous or subcutaneous) for certain conditions to be experimental, investigational, or unproven because effectiveness has not been established. Examples of indications listed as not established include Crohn's disease, multiple forms of non-infectious uveitis and other ocular inflammatory disorders (e.g., panuveitis, posterior uveitis, scleritis), and sarcoidosis of the lung. Corresponding ICD-10 codes for these non-covered or investigational indications are listed in the policy (for example, K50.x for Crohn's disease; H20.x–H21.x for ocular inflammatory disorders; D86.0 for pulmonary sarcoidosis).

    Concomitant administration of Simponi (golimumab) with other biologic agents such as abatacept or with anakinra is not recommended. The policy notes that combining a TNF blocker with abatacept or anakinra was associated with a higher risk of serious infections; therefore, concomitant use of these products and Simponi is discouraged and considered an experimental/unproven approach when used with other biologics for the same indication.

    For ulcerative colitis (UC), coverage aligns with the studied and FDA-approved dosing schedules. The policy cites the PURSUIT/phase 2/3 trials and the approved adult induction/maintenance regimen (200 mg at Week 0, 100 mg at Week 2, then 100 mg every 4 weeks). Use of golimumab outside the studied or approved dosing schedule or in patients with prior exposure to TNF inhibitors (when such patients were excluded from the trials) is considered unsupported unless adequate justification is provided; intravenous administration for UC is listed among indications considered experimental/investigational.

    A randomized, placebo-controlled trial in patients with severe persistent asthma did not demonstrate clinical benefit for golimumab and showed an unfavorable risk–benefit profile, with higher rates of serious adverse events and discontinuations in the active treatment groups. As a result, golimumab is not supported for the treatment of asthma.

    Clinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute offers of coverage or medical advice. They provide a partial, general description of plan benefits and do not form a contract; treating providers remain responsible for medical decisions and should follow plan-specific prior authorization processes where applicable.

    Concomitant use of golimumab with another biologic or targeted synthetic agent for the same indication is considered not established and therefore experimental/investigational per the policy. Requests for dual biologic or dual targeted-synthetic therapy for the same indication may be denied unless robust evidence and clinical justification are provided.

    Simponi (subcutaneous golimumab) is not FDA-indicated for nonradiographic axial spondyloarthritis (nr-axSpA); however, compendia and clinical references cited in the policy support off-label consideration in patients who have had an inadequate response to two different NSAIDs used consecutively. Because an FDA indication is absent, coverage decisions for nr-axSpA may depend on compendial support and documented failure of recommended prior therapies.

    Pediatric dosing for subcutaneous golimumab in ulcerative colitis is supported only for children meeting the studied population criteria. The policy highlights the FDA pediatric approval for UC in children weighing at least 15 kg based on the pediatric PURSUIT 2 study; use in pediatric patients <15 kg is not supported by the cited efficacy population and would be considered not medically necessary without additional evidence.

    Use of golimumab for Crohn's disease and for pulmonary sarcoidosis is not supported by guideline recommendations or randomized trial evidence. UpToDate reviews do not recommend golimumab for moderate-to-severe Crohn's disease, and randomized trials in pulmonary sarcoidosis did not demonstrate effectiveness; therefore these indications are considered investigational/unsupported absent compelling specialty documentation.

    Coding and Product Information

    Relevant CPT/HCPCS/Lab Codesmixed
    J1602Injection, golimumab, 1 mg, for intravenous use [Simponi Aria only]
    71045-71048Radiologic examination, chest
    85651Sedimentation rate, erythrocyte; non-automated
    85652Sedimentation rate, erythrocyte; automated
    86140C-reactive protein
    86141C-reactive protein; high sensitivity (hsCRP)
    86200Cyclic citrullinated peptide (CCP), antibody
    86430Rheumatoid factor; qualitative
    86431Rheumatoid factor; quantitative
    86480Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon
    1–10 of 17
    1/2
    Other related HCPCS codes (comparators/adjuncts)HCPCS
    J0139Injection, adalimumab, 1 mg
    J0717Injection, certolizumab pegol, 1 mg
    J1438Injection, etanercept, 25 mg
    J1745Injection, infliximab, 10 mg
    J9312Injection, rituximab, 10 mg
    Q5109Injection, infliximab-qbtx (biosimilar), 10 mg
    Q5140-Q5145Injection, adalimumab biosimilars, 1 mg (various)
    J8610Methotrexate, oral, 2.5 mg
    ICD-10 Codes Covered/Not CoveredICD-10
    K51.00-K51.919Ulcerative colitis
    K50.00-K50.919Crohn's disease
    L40.50-L40.59Arthropathic psoriasis
    M05.00-M06.9Rheumatoid arthritis
    M08.00-M08.99Juvenile idiopathic arthritis
    M45.0-M45.ABAnkylosing spondylitis
    M13.80-M13.89Other specified arthritis (including immune checkpoint inhibitor toxicity)
    T45.AX5A-T45.AX5SAdverse effect of immune checkpoint inhibitors and immunostimulant drugs
    H20.00-H21.29Disorders of iris and ciliary body (ocular inflammatory disorders)
    J45.20-J45.998Asthma
    1–10 of 11
    1/2
    Product presentations / supplymixed
    50 mg/4 ml vialSimponi Aria supplied as individually boxed single-use vials (50mg/4ml) - product presentation referenced
    Brands and FDA labeled indicationsmixed
    Simponigolimumab — FDA labeled indications include ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
    Simponi Ariagolimumab intravenous — FDA labeled indications include ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis
    Pediatric weight threshold for UC dosing
    Pediatric weight threshold for UC dosing>= 15 kg (pediatric patients included in PURSUIT 2 and reflected in label dosing tiers)
    Pediatric dosing tiers referencedStudy used BSA-based dosing for 15 kg to <45 kg (120 mg/m2 Week 0; 60 mg/m2 Week 2; 60 mg/m2 every 4 weeks thereafter) but label provides weight-tiered recommendations for 15 kg to <40 kg and >=40 kg
    Study efficacy population noteEfficacy evaluated in 66 pediatric subjects weighing at least 15 kg (Mayo score 6–12; endoscopy subscore ≥2)
    Pediatric weight threshold for studied population
    Studied pediatric population weight threshold≥15 kg (PURSUIT 2 evaluated efficacy in patients ≥15 kg)
    Studied age rangeParticipants 4 to 17 years (mean age 13.4 years) in PURSUIT 2; study enrolled pediatric patients aged ≥2 years but efficacy analysis included those ≥15 kg
    Prior TNF exposure exclusionPatients with prior exposure to TNF blockers were excluded from the PURSUIT 2 efficacy cohort

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; follow FDA dosing limits

    Prior authorization is required for golimumab; approvals are subject to dosing limits consistent with FDA labeling and specialty medication quantity limits. Simponi Aria (IV) should be billed using HCPCS J1602 (injection, golimumab, 1 mg).

    • Approvals subject to FDA-approved labeling, compendia, and Medical Specialty Medication Quantity Limits.
    • Simponi Aria intravenous billing: J1602 (injection, golimumab, 1 mg).
    Prior Authorization

    PA must reflect FDA-approved and compendial indications

    Submit PA requests that align with FDA-approved indications and recognized compendial uses (e.g., RA in combination with methotrexate; PsA; AS; UC in adults and pediatric patients ≥15 kg). Documentation may need to show prior therapy or inadequate response where applicable.

    • Covered indications include RA (with MTX), PsA, AS, and UC (adult and pediatric ≥15 kg).
    • Compendial/off-label uses (e.g., nr-axSpA) may be considered when supported by documentation of prior therapy failures.
    Prior Authorization

    Confirm indication and prior therapy in PA

    PA must verify the specific indication matches FDA approvals or supported compendial uses and confirm prior treatment failures or contraindications per the trial/label context (for example, inadequate response to conventional therapy).

    • Confirm indication (e.g., moderate-to-severe UC, RA, PsA, AS, pJIA) matches label or compendia.
    • Verify prior treatments and documented inadequate response or contraindication when trials required prior therapy failures.
    Prior Authorization

    Document prior DMARD trials and rationale for biologic escalation

    For RA, prior authorization should document attempted conventional DMARD therapy (including methotrexate) and the clinical rationale for escalation to a biologic when treatment targets were not met, consistent with guideline-recommended sequencing.

    • Document trials of conventional DMARDs and reason for inadequate response or intolerance.
    • Reference EULAR/ACR guidance supporting escalation from methotrexate to a TNF inhibitor when targets are unmet.
    Note

    Follow plan-specific PA and administration guidance

    Follow the Clinical Policy Bulletin and any plan-specific prior authorization processes listed; the bulletin is intended to assist in administering plan benefits and links to administrative notes and definitions.

    • Use linked Clinical Policy Bulletin Notes and Definitions for plan-specific PA instructions.
    • Policy history and review dates are provided for reference.
    Step Therapy

    Document expected combination or sequence of therapies

    Document combination therapy expectations per indication: for RA, golimumab is recommended in combination with methotrexate; for PsA or AS, golimumab may be given with or without methotrexate or other nonbiologic DMARDs.

    • RA: Simponi/Simponi Aria should be given with methotrexate.
    • PsA/AS: SC golimumab may be used with or without methotrexate or other nonbiologic DMARDs.
    Step Therapy

    Require documentation of prior DMARD/NSAID therapy

    PA should show trials of conventional DMARDs (including methotrexate) for RA and, where applicable, trials of two different NSAIDs for nr-axSpA before TNF inhibitor use, unless contraindicated.

    • NICE guidance: trials of 2 DMARDs including methotrexate for RA unless contraindicated.
    • nr-axSpA: compendia/UpToDate recommend inadequate response to two different NSAIDs used consecutively.
    Step Therapy

    Document guideline-based sequencing with methotrexate first-line

    Methotrexate is the preferred first-line DMARD for RA per guidelines; escalation to a TNF inhibitor such as golimumab should be documented when methotrexate monotherapy fails or is contraindicated.

    • EULAR/ACR recommend methotrexate as preferred initial DMARD for RA.
    • If targets not met within 3–6 months, escalation to a biologic DMARD is advised.
    Step Therapy

    Document exceptions to step therapy and reference Appendix A

    When bypassing step therapy (e.g., not using methotrexate first), providers must document clinical reasons or exceptions as listed in Appendix A (such as pregnancy, liver disease, allergy, or other contraindications).

    • Appendix A lists acceptable clinical reasons to avoid methotrexate (e.g., pregnancy, liver disease, hypersensitivity).
    • Documented rationale must accompany requests that do not follow standard step sequencing.
    Note

    Refer to full policy for step therapy specifics when absent

    If the policy text does not include specific step therapy algorithms for an indication, refer the reviewer to the full policy and linked Clinical Policy Bulletin Notes for plan-specific step therapy requirements and exceptions.

    • Full policy and Clinical Policy Bulletin Notes contain administrative and step therapy specifics.
    • Contact plan/PA reviewer for any insurer-specific step requirements not detailed in the excerpt.
    Documentation Required

    Document dosing regimen and indication in the medical record

    Provide documentation supporting the prescribed dosing regimen and indication: IV Simponi Aria dosing (2 mg/kg at weeks 0 and 4, then every 8 weeks) and SC Simponi dosing (50 mg monthly for RA/PsA/AS; UC induction/maintenance per label) must be clearly recorded.

    • Simponi Aria IV: 2 mg/kg IV infusion over 30 minutes at weeks 0 and 4, then every 8 weeks.
    • Simponi SC: 50 mg by subcutaneous injection once monthly for RA/PsA/AS; UC dosing per recommended table and weight tiers.
    Documentation Required

    Perform and document TB screening and infection monitoring

    Document latent tuberculosis testing before initiation and ongoing monitoring for active TB during treatment; TB testing within 12 months prior to starting a biologic should be in the record per CDC Quality ID #176.

    • Perform and document TB screening within 12 months prior to initiating biologic therapy when indicated.
    • If latent TB is positive, start TB treatment prior to initiating golimumab and monitor for active TB during therapy.
    Documentation Required

    Document patient age, weight, and prior therapies

    Include patient demographic and treatment history details in the PA: age, weight (especially for pediatric UC dosing thresholds ≥15 kg), prior therapies and whether the patient is TNF-alpha antagonist naive or experienced.

    • Document patient age and weight; pediatric UC dosing applies to patients weighing at least 15 kg.
    • Record prior therapies (e.g., MTX, corticosteroids, 6-MP, azathioprine) and prior TNF exposure status.
    Documentation Required

    Include supportive references and prescribing information

    Cite the prescribing information and guideline references included in the policy when submitting PA or medical record documentation to support dosing, prior therapy, and safety screening decisions.

    • References and PI provide the basis for labeled dosing and safety monitoring expectations.
    • Use cited guideline documents (ACR, EULAR, NICE) to justify sequencing and prior therapy requirements.
    Note

    Reference policy history and review dates

    Reference the policy history and review dates when needed; the document lists last review 07/31/2026 and next review 08/27/2026 for administrative context.

    • Last review date: 07/31/2026; Next review: 08/27/2026.
    • Use Clinical Policy Bulletin Notes and Definitions links for administrative details.
    Denial Risk

    Denial risk: concomitant biologics or unproven IV uses

    Requests for concomitant use of golimumab with another biologic or targeted synthetic agent for the same indication, or IV golimumab for indications listed as unproven, may be denied because these uses are considered experimental or investigational.

    • Concomitant use with another biologic (e.g., adalimumab, etanercept) or targeted synthetic (e.g., tofacitinib) is considered experimental/investigational.
    • IV golimumab is considered unproven for indications such as Crohn's disease, Behcet's disease, and non-infectious uveitis.
    Denial Risk

    Denial risk if TB screening not documented before initiation

    Initiating Simponi without documented latent TB testing within the prior 12 months or without TB screening documentation may increase the risk of coverage denial given the boxed warning and CDC Quality ID #176 recommendations.

    • Policy and CDC guidance require TB screening documentation prior to starting biologic therapies with TB reactivation risk.
    • Lack of TB testing documentation may trigger denial or request for additional information.
    Denial Risk

    Denial risk for use outside FDA pediatric weight/indication

    Use of subcutaneous Simponi in pediatric patients under 15 kg or other uses outside FDA-labeled pediatric weight/indication may be considered not medically necessary and risk denial if medical records do not support the off-label use.

    • FDA pediatric UC approval applies to patients weighing at least 15 kg; PURSUIT data focused on ≥15 kg.
    • Requests for dosing outside studied weight tiers should include robust supporting evidence.
    Denial Risk

    Denial risk if safety-related documentation (serious infections/deaths) is absent

    Failure to document safety screening and risk assessment (e.g., for serious infections reported in trials, including TB and reported deaths) may lead to denial or request for additional information before approval.

    • IV golimumab trials reported increased infections, one TB case, and at least one death; safety screening documentation is expected.
    • Documented infectious risk assessment and monitoring plans should be included in the record.
    Note

    Clinical Policy Bulletins are administrative, not coverage guarantees

    Clinical Policy Bulletins are administrative tools to assist in benefit management and do not constitute offers of coverage or clinical recommendations; providers remain responsible for treatment decisions and must follow plan provisions to avoid coverage issues.

    • Bulletins contain only a partial description of plan benefits and are not a contract.
    • Providers are solely responsible for medical advice and must adhere to plan prior authorization processes.

    Background and Therapy Overview

    Golimumab is a human monoclonal antibody that binds and neutralizes tumor necrosis factor alpha (TNF-α). It is marketed in subcutaneous form as Simponi and in intravenous form as Simponi Aria. Elevated TNF-α contributes to chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; golimumab reduces TNF-α–mediated inflammation and has demonstrated efficacy versus placebo in randomized trials for several approved indications.

    Definitions and References

    TNF-alpha inhibitor definition
    DefinitionTumor necrosis factor (TNF)-alpha inhibitor: a biologic agent that binds and blocks TNF-alpha to reduce inflammation.
    MechanismBinds and neutralizes TNF-alpha, preventing interaction with cell-surface TNF receptors and inhibiting downstream inflammation.
    Clinical relevanceUsed to treat chronic inflammatory diseases where elevated TNF-alpha contributes to disease pathophysiology (e.g., RA, PsA, AS).
    Golimumab (Simponi) definition
    Agent and formulationGolimumab (Simponi): a human monoclonal antibody TNF-alpha blocker available as subcutaneous Simponi and intravenous Simponi Aria.
    Mechanism of actionBinds soluble and transmembrane forms of TNF-alpha, inhibiting its biological activity.
    FDA-approved indications (selected)Includes moderately to severely active RA (with methotrexate), PsA, AS, and moderately to severely active ulcerative colitis (adults and pediatric patients ≥15 kg).
    Axial spondyloarthritis (axSpA) definition
    DefinitionAxial spondyloarthritis (axSpA): a group of inflammatory arthritis conditions primarily affecting the spine, including ankylosing spondylitis (radiographic) and nonradiographic axial spondyloarthritis (nr-axSpA).
    Clinical featuresTypically presents with chronic back pain beginning before age 45; diagnosis requires a combination of clinical and imaging findings (e.g., MRI sacroiliac inflammation).
    SubclassificationAS demonstrates radiographic sacroiliitis; nr-axSpA lacks or has minimal radiographic changes but may show MRI inflammation.
    ACR20/50/70 definition
    ACR20/50/70 explainedACR20/50/70: American College of Rheumatology criteria denoting at least 20%, 50%, or 70% improvement in RA signs and symptoms used as primary efficacy endpoints in RA and related trials.
    Clinical useCommonly reported endpoints in trials of golimumab (e.g., I.V. golimumab + MTX showed 59% ACR20 and 30% ACR50 at week 14).
    InterpretationHigher ACR percentages indicate greater clinical improvement in joint counts and other RA activity measures.
    ASAS20 definition
    ASAS20 definitionASAS20: Assessment in Ankylosing Spondylitis 20% response — a composite endpoint indicating at least 20% improvement used as the primary endpoint in ankylosing spondylitis trials.
    Trial usePrimary endpoint in Go-ALIVE study of IV golimumab for AS (assessed at week 16).
    Related endpointsASAS40, BASDAI50 and other measures are used alongside ASAS20 to assess higher levels of response and function.
    ACR20 / ACR50 (duplicate definition entry)
    ACR20 / ACR50 duplicate definitionAmerican College of Rheumatology criteria indicating at least 20% (ACR20) or 50% (ACR50) improvement in rheumatoid arthritis signs and symptoms as used in clinical trials (e.g., IV golimumab + MTX showed 59% ACR20 and 30% ACR50 at week 14).
    Usage noteThese measures are standard endpoints for efficacy in RA and PsA trials and inform coverage continuation assessments.
    Evidence exampleI.V. golimumab plus methotrexate demonstrated significant ACR20/50 improvements versus placebo in randomized trials (see trial reports).
    References (bibliography list pointers)
    References listComprehensive bibliography of clinical trials, guidelines, prescribing information, and reviews underpinning policy recommendations (References 1–78 and continuing).
    Key guideline sourcesIncludes ACR, EULAR, ASAS/EULAR guidance and AGA/UpToDate references cited in the policy references section.
    Prescribing informationSimponi prescribing information (Centocor Ortho Biotech/ Janssen) and trial publications (e.g., Go-VIBRANT, Go-ALIVE, PURSUIT) are cited for dosing and evidence summaries.